The SSADH Association is a voluntary, not-for-profit, 501(c) (3) organization dedicated to helping children and families affected by an ultra-rare neurometabolic disorder known as Succinic Semialdehyde Dehydrogenase Deficiency or SSADH.
The SSADH Association is committed to those affected with this neurotransmitter disease through education, advocacy and research.
News & Updates
GC Pharma and Speragen Announce Joint Development of SSADHD Enzyme Replacement Therapy and License Agreement of the patent of SSADH Protein generation plasmid
GC Pharma and Speragen Announce Joint Development of SSADHD EnzymeReplacement Therapy and License Agreement of the patent of SSADH Proteingeneration…Read More
The SSADH Association awarded $55,000 to Henry Lee, Ph.D., Alexander Rotenberg, Ph.D., MD, and Phil Pearl, MD from Boston Children’s Hospital /…Read More
The SSADH Association committed $50,000 for a fellowship program with Dr. Jens Andersen at the University of Copenhagen, Denmark to…Read More
The 2020 Virtual SSADH Conference was held July 9 and 10, 2020 was a huge success! We are happy to share that we had over 300 individuals register, representing 25 countries.
Below are the links to the recording for each session. The recordings will be available until early 2021.
2020 SSADH Conference - Session 1
2020 SSADH Conference - Session 2
2020 SSADH Conference - Session 3
2020 SSADH Conference - Session 4
Additionally, the proceedings from this conference are being published as individual manuscripts in the Journal of Child Neurology. As they become available they will be posted under the news section. To read the articles click here.
Many thanks to the Conference Organizers: Dr. Jean-Baptiste Roullet, Dr. K. Michael Gibson
Dr. Phillip Pearl, Dr. Melissa DiBacco, Alice McConnell, & Carolyn Hoffman